A Case of Metastatic Melanoma in a Female Patient with Vitiligo
Main Article Content
Abstract
Patients with metastatic melanoma occasionally develop de novo hypopigmentation, pathologically indistinguishable from Sutton's nevus and common vitiligo, respectively. The case of a 68-year-old female with vitiligo of 2 years of evolution is documented, presenting a left inguinal mass and a para-aortic lymph node conglomerate. In the left inguinal region, a ganglion with thickened cortex and liquid content was identified. The laboratory results report hemoglobin of 8.30 g/dL, leukocytes 19.12 u/L, albumin 2.2 mg/dl, DHL 1222 Ul/L, alpha-fetoprotein 2 ng/ml, Ca-125 14.30 U/ml, Ca-19.9 8.60 U/ml and carcinoembryonic antigen of 2.14 ng/ml. Upon inspection, hypochromic, bilateral, and symmetrical lesions can be seen on the back of the hands, wrists, scalp, facial region, and neck. Biopsy showing malignant metastatic melanoma is performed. Starting management with Pembrolizumab 1 mg/kg every 21 days. Currently in follow-up and adjuvant treatment. Melanoma is the most aggressive form of skin cancer. The association of malignant melanoma with de novo hypopigmentation has been found, synchronously or following the diagnosis of the tumor. In recent years, it has led to the development of monoclonal antibodies. However, its diagnosis has implications for life prognosis due to high mortality.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Failla C. M, Carbone ML, Fortes C, Pagnanelli G, D’Atri, S. Melanoma and vitiligo:
II. In good company. International Journal of Molecular Sciences.2019: 20, 5731.
III. Taïeb A, Picardo M, other VETF members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res. 2007; 20: 27-35.
IV. Camacho Limas CP, Gerson Cwilich R, Góngora Jurado MA, Villalobos Prieto A, Blanco Vázquez YC, López Riverol O. Actualidades para el tratamiento del melanoma metastásico. 2017; 62(3):196-207.
V. Pique E, Palacios S, Martinez M, Perez JA. Complete regression of melanom associated with vitiligo. Dermatol Online J. 2011;17(1):4.
VI. Westerhof W, Manini P, Napolitano A, D’ischiam. The haptenation theory of vitiligo and melanoma rejection: a close-up. Exp Dermatology. 2011;20(2):92-6.
VII. Cohen BE, Manga P, Lin K, Elbuluk N. Vitiligo, and melanoma-associated vitiligo:
VIII. Understanding their similarities and differences. Am J Clin Dermatol. 2020;21(5):669–80.
IX. Gamarra A, Sáenz E, Del Carmen Sialer M, Tejada E, Álvarez P. Metastatic amelanotic melanoma associated vitíligo. Folia dermatol. peru ; 23(2): 81-86, may.- ago.2012.
X. Hernández DDA, Aldaco SF, Cervantes SG, Erazo VSAA, Pérez PP, Torrecillas TL, Cortés EP, et al. La mortalidad por melanoma en México aumenta. Rev Esp Méd Quir. 2018;23: 124-129.
XI. SEOM. Informe SEOM de evaluación de Pembrolizumab, https://seom.org/seomcms/images/stories/Informes_SEOM/Informe_SEOM_de_Pe mbrolizumab.pdf